EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

AMNEAL PHARMACEUTICALS, INC. (AMRX) had EBITDA of $129.45M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$784.51M
Net Income	$2.37M
Cost of Goods Sold	$510.54M
Gross Profit	$273.97M
Operating Expenses	$714.17M
Operating Income	$70.34M
Non-Operating Income/Expense	$-75.57M
Pre-Tax Income	$-5.22M
Normalized Pre-Tax Income	$-5.22M
Income after Taxes	$18.13M
Income from Continuous Operations	$18.13M
Consolidated Net Income/Loss	$18.13M
Normalized Income after Taxes	$18.13M
EBIT	$70.34M
EBITDA	$129.45M
Weighted-Average Shares Outstanding (Basic)	314.17M
Weighted-Average Shares Outstanding (Diluted)	324.75M
Earnings per Share (EPS) (Basic)	$0.01
Earnings per Share (EPS) (Diluted)	$0.01
Balance Sheet Financials
Current Assets	$1.84B
Property, Plant, and Equipment	$434.99M
Long-Term Assets	$1.76B
Total Assets	$3.60B
Current Liabilities	$862.11M
Long-Term Debt	$2.57B
Long-Term Liabilities	$2.85B
Total Liabilities	$3.71B
Common Equity	$-109.95M
Tangible Shareholders Equity	$-1.29B
Shareholders Equity	$-109.95M
Common Shares Outstanding	314.31M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$209.68M
Cash Flow from Investing Activities	$-66.81M
Cash Flow from Financial Activities	$-21.41M
Beginning Cash	$118.42M
End Cash	$238.41M
Increase/Decrease in Cash	$119.99M
Stock-Based Compensation	$23.75M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.13
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.04
Debt to Equity Ratio	-23.41
Gross Margin	34.92%
Operating Margin	8.97%
EBIT Margin	8.97%
EBITDA Margin	--
Pre-Tax Profit Margin	-0.67%
Profit Margin	0.30%
Free Cash Flow	$155.38M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.83
Receiveable Turnover	0.89
Days Sales in Receivables	101.70
Return on Equity	-16.49%
Return on Tangible Equity	-1.40%
Return on Assets	0.50%
Return on Investments	0.74%
Book Value Per Share	$-0.35
Free Cash Flow per Share	$0.48
Operating Cash Flow per Share	$0.65

Data from Zacks Investment Research, Inc.